01—Abstract
Summary
Summary of the 10-K filed February 10, 2011. Cited figures are marked; the original filing is the authoritative source.
Neurocrine Biosciences, Inc. (NBIX) reported a net loss of $8.0 milliona, or $0.15 per share, for 2010, sharply narrower than the $51.0 million net loss in 2009.
Total revenues rose to $33.5 millionb from $3.0 million, driven by the June 2010 collaborations with Abbott International Luxembourg S.à r.l. and Boehringer Ingelheim International GmbH. Cash, cash equivalents and investments totaled $130.6 million at December 31, 2010, compared with $59.9 million a year earlier, and the company had an accumulated deficit of $762.3 million. The company says it expects to be profitable in 2011 mainly because of a full year of activity under those collaborations, but does not expect to be operating cash flow positive in 2011 or to remain profitable beyond 2011.
The lead program is elagolix, an oral GnRH antagonist for endometriosis that is partnered with Abbott. Abbott paid a $75 millionc upfront payment and may pay up to approximately $530 million in milestones. The company and Abbott have scheduled an end-of-Phase II meeting with the FDA in March 2011, and the company expects elagolix to enter Phase III trials in 2011, subject to FDA agreement on the trial design.
The FDA-requested modified daily pain scales were used in the 901 study, which showed improvement in the elagolix arms. The filing also notes that the CRF1 antagonist 561679 showed no benefit over placebo in a Phase II major depressive disorder trial, and that indiplon has received an approvable letter from the FDA with new requirements, after which clinical development in the United States ceased.
Financing sources include a $125 milliond shelf registration declared effective in December 2010 and a Committed Equity Financing Facility with Kingsbridge Capital Limited for up to $75 million, under which no shares had been issued as of year-end. Operating risks are concentrated in the clinical trial outcomes, dependence on collaborators, the need for future funding, and reliance on third-party manufacturers.
02—Key points
Key Highlights
- Net loss narrowed to $8.0 million ($0.15 per share) in 2010 from $51.0 million in 2009, and the company expects to be profitable in 2011.
- Total revenues increased to $33.5 million in 2010 from $3.0 million in 2009, driven mainly by the Abbott and Boehringer Ingelheim collaborations.
- Abbott made a $75 million upfront payment for elagolix and next-generation GnRH antagonists, with up to approximately $530 million in additional milestones.
- Elagolix (endometriosis) is expected to enter Phase III in 2011, subject to FDA agreement on trial design at an end-of-Phase II meeting scheduled for March 2011.
- Cash, cash equivalents and investments totaled $130.6 million at December 31, 2010, up from $59.9 million at December 31, 2009.
- The CRF1 antagonist 561679 showed no benefit compared with placebo in a Phase II major depressive disorder trial.
- Accumulated deficit was $762.3 million at December 31, 2010, and the company does not expect operating cash flow to be positive in 2011.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2010filed February 10, 2011Financial Statements
FY2010 against FY2009
| Line item | FY2010FY2009 | Change |
|---|---|---|
| Revenue | $33.50M$2.95M | +1034.5% |
| R&D Expenses | $31.15M$33.72M | −7.6% |
| Operating Expenses | $47.22M$56.62M | −16.6% |
| Operating Income | -$13.72M-$53.67M | +74.4% |
| Net Income | -$7.97M-$51.04M | +84.4% |
| EPS (Basic) | $-0.15$-1.30 | +88.5% |
| EPS (Diluted) | $-0.15$-1.30 | +88.5% |
| Shares Outstanding (Basic) | 52.82M39.14M | +35.0% |
| Shares Outstanding (Diluted) | 52.82M39.14M | +35.0% |
05—Questions
Frequently Asked Questions
Why did the net loss shrink so much in 2010?
The filing attributes the decrease to revenue recognized under the Abbott and Boehringer Ingelheim collaboration agreements, the restructuring program implemented in the second quarter of 2009, and expense management during 2010. Total revenues were $33.5 million in 2010 compared with $3.0 million in 2009, while total operating expenses were $47.2 million compared with $56.6 million.
What is the near-term catalyst for the company's lead program?
The company and Abbott scheduled an end-of-Phase II meeting with the FDA in March 2011 to agree on the design of the pivotal Phase III program for elagolix in endometriosis. Subject to that agreement, the company expects elagolix to enter Phase III trials in 2011.
Does the company have enough cash to fund operations?
The company believes its existing capital resources, investment income and future payments under its strategic alliances will be sufficient to meet its current and projected funding requirements for at least the next 12 months. It also states that it will need additional funding for ongoing programs and may seek it through equity markets, the $125 million shelf registration, or the Kingsbridge CEFF of up to $75 million, which had not been used as of December 31, 2010.
What happened with indiplon?
The FDA issued an approvable letter in December 2007 for indiplon 5mg and 10mg capsules, but set new requirements, including an elderly clinical trial, a safety study comparing adverse event rates with a marketed product, and a preclinical third-trimester pregnancy study. After receiving that letter, the company ceased all indiplon clinical development and pre-commercialization activities in the United States and continues to evaluate alternatives for the program.
06—Continue